Asset Details
Do you wish to reserve the book?
Safety of transarterial chemoembolization on renal function in combined hepatocellular carcinoma and chronic kidney disease patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Safety of transarterial chemoembolization on renal function in combined hepatocellular carcinoma and chronic kidney disease patients
Do you wish to request the book?
Safety of transarterial chemoembolization on renal function in combined hepatocellular carcinoma and chronic kidney disease patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Safety of transarterial chemoembolization on renal function in combined hepatocellular carcinoma and chronic kidney disease patients
2025
Overview
This study was to investigate the safety of transarterial chemoembolization (TACE) which required injection of contrast medium on renal function in combined hepatocellular carcinoma and chronic kidney disease (CKD) patients. A total of 265 patients admitted for the first session of TACE were included for analysis. CKD was defined as Cockcroft‐Gault glomerular filtration rate (CG‐GFR) < 60 mL/min/1.73 m2. The odds ratio (OR) and 95% confident interval (CI) were calculated to show the influence of factors on renal function. Overall, 24.07% patients with CKD and 31.21% patients without CKD showed exacerbated renal function at discharge. However, 73.15% patients with CKD and 63.69% patients without CKD showed significantly improved renal function (all p = 0.00001). No significant difference in influence of TACE on renal function between patients with and without CKD (p = 0.20509). Factors to exacerbate the serum creatinine level at the third day after TACE included proteinuria ≥1+ (OR 2.2469, 95% CI = 1.1559–4.3675) and glycated hemoglobin ≥7% (OR 2.0796, 95% CI = 1.0497–4.1200). These factors could be obliterated by admission for more than 3 days after TACE. Serum albumin level <3 g/dL at admission was the only factor to exacerbate renal function at discharge (OR 4.4179, 95% CI = 1.3964–13.9776). In conclusion, TACE exerted same influence on renal function between patients with and without CKD. Most patients showed improved renal function at discharge. Low serum albumin level, proteinuria and poor diabetes mellitus control were factors to exacerbate renal function after TACE.
Publisher
Wiley Publishing Asia Pty Ltd,John Wiley & Sons, Inc
Subject
/ Adult
/ Aged
/ Alcohol
/ Carcinoma, Hepatocellular - blood
/ Carcinoma, Hepatocellular - complications
/ Carcinoma, Hepatocellular - therapy
/ Chemoembolization, Therapeutic - adverse effects
/ Chemoembolization, Therapeutic - methods
/ Cockcroft‐Gault glomerular filtration rate
/ contrast‐induced nephropathy
/ Diabetes
/ Epirubicin - administration & dosage
/ Epirubicin - adverse effects
/ Female
/ Glomerular Filtration Rate - physiology
/ Glycated Hemoglobin - analysis
/ Humans
/ Liver Neoplasms - complications
/ Male
/ Original
/ Patients
/ Proteinuria - physiopathology
/ Renal Insufficiency, Chronic - blood
/ Renal Insufficiency, Chronic - complications
/ Renal Insufficiency, Chronic - diagnosis
